Disseminated Tumor Cells in Bone Marrow Assessed by TWIST1, Cytokeratin 19, and Mammaglobin A mRNA Predict Clinical Outcome in Operable Breast Cancer Patients

2010 ◽  
Vol 10 (5) ◽  
pp. 378-384 ◽  
Author(s):  
Kjersti Tjensvoll ◽  
Satu Oltedal ◽  
Ragne K. Farmen ◽  
Fuad V. Shammas ◽  
Reino Heikkilä ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Disseminated Tumor Cells ◽  
Operable Breast Cancer ◽  
Cytokeratin 19 ◽  
Breast Cancer Patients

scholarly journals Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Kjersti Tjensvoll ◽  
Oddmund Nordgård ◽  
Maren Skjæveland ◽  
Satu Oltedal ◽  
Emiel A. M. Janssen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Cox Regression ◽  
Disseminated Tumor Cells ◽  
Operable Breast Cancer ◽  
Breast Cancer Patients ◽  
Primary Tumors ◽  
Post Surgery

Abstract Background Operable breast cancer patients may experience late recurrences because of reactivation of dormant tumor cells within the bone marrow (BM). Identification of patients who would benefit from extended therapy is therefore needed. Methods BM samples obtained pre- and post-surgery were previously analysed for presence of disseminated tumor cells (DTC) by a multimarker mRNA quantitative reverse-transcription PCR assay. Updated survival analyses were performed on all patient data (n = 191) and in a subgroup of patients alive and recurrence-free after 5 years (n = 156). DTC data were compared to the mitotic activity index (MAI) of the primary tumors. Median follow-up time was 15.3 years. Results Among the 191 patients, 49 (25.65%) experienced systemic relapse, 24 (49%) within 5–18 years after surgery. MAI and pre- and post-operative DTC status had significant prognostic value based on Kaplan–Meier analyses and multiple Cox regression in the overall patient cohort. With exclusion of patients who relapsed or died within 5 years from surgery, only pre-operative DTC detection was an independent prognostic marker of late recurrences. High MAI (≥10) did not predict late recurrences or disease-specific mortality. Conclusion Pre-operative DTC detection, but not MAI status, predicts late recurrences in operable breast cancer.

Disseminated tumor cells in bone marrow of breast cancer patients–Comparison of immunocytochemistry and RT-PCR

2006 ◽  
Vol 66 (S 01) ◽  
Author(s):  
T Fehm ◽  
S Becker ◽  
MJ Banys ◽  
G Becker-Pergola ◽  
S Duerr-Stoerzer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Disseminated Tumor Cells ◽  
Breast Cancer Patients ◽  
Rt Pcr

Detection and prevalence of disseminated tumor cells from the bone marrow of early stage male breast cancer patients

2015 ◽  
Vol 152 (1) ◽  
pp. 51-55 ◽  
Author(s):  
Andreas D. Hartkopf ◽  
Florin-Andrei Taran ◽  
Christina B. Walter ◽  
Markus Hahn ◽  
Tanja Fehm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Male Breast Cancer ◽  
Early Stage ◽  
Disseminated Tumor Cells ◽  
Male Breast ◽  
Breast Cancer Patients

Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen–Friedenreich tumor antigen

2005 ◽  
Vol 123 (6) ◽  
pp. 631-637 ◽  
Author(s):  
Christian Schindlbeck ◽  
Udo Jeschke ◽  
Sandra Schulze ◽  
Uwe Karsten ◽  
Wolfgang Janni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Tumor Antigen ◽  
Disseminated Tumor Cells ◽  
Breast Cancer Patients

Prognostic impact of Thomsen–Friedenreich tumor antigen and disseminated tumor cells in the bone marrow of breast cancer patients

2006 ◽  
Vol 101 (1) ◽  
pp. 17-25 ◽  
Author(s):  
Christian Schindlbeck ◽  
Udo Jeschke ◽  
Sandra Schulze ◽  
Uwe Karsten ◽  
Wolfgang Janni ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Tumor Antigen ◽  
Disseminated Tumor Cells ◽  
Prognostic Impact ◽  
Breast Cancer Patients

Estrogen receptor (ER) status of disseminated tumor cells in the bone marrow of breast cancer patients

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21013-21013
Author(s):  
F. N. Tanja ◽  
N. Krawczyk ◽  
D. Wallwiener ◽  
S. Becker ◽  
E. Solomayer
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Primary Tumor ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Disseminated Tumor Cells ◽  
Breast Cancer Patients ◽  
Primary Tumors

21013 Background: The presence of disseminated tumor cells (DTC) in bone marrow (BM) of primary breast cancer patients is associated with poor prognosis. These patients may benefit from adjuvant endocrine therapy since cytotoxic agents are not able to completely eliminate DTCs as previously shown. Only patients with hormone receptor positive breast cancer are eligible for hormonal treatment. The ERa status is routinely defined in primary tumor tissue. However, the ERa status of DTC may differ compared to the primary tumor. Therefore, the aims of this study were (1) to determine the ERa status of DTC in BM of breast cancer patients, (2) and to compare the ERa status of DTC and corresponding primary tumors. Methods: BM aspirates from 251 primary breast cancer patients were included into the study. A double immunofluorescence staining procedure was established for the identification of cytokeratin-positive (CK)/ERa positive cells. ERa status of the primary tumor was immunohistochemically assessed using the same antibody against ERa. Results: In 105 of 251 (42%) breast cancer patients CK-positive cells could be detected in BM. The number of detected cells ranged between 1 and 13 / cells per 2*106 mononuclear cells. Disseminated tumor cells demonstrated ERa positivity in 13 (12%) of these 105 patients. The ERa expression on DTC was heterogeneous in 10 of 13 (79%) patients. Concordance rate of ERa status between primary tumor and DTC was 27%. Only 11 of 83 patients with ER a positive tumors had also ERa positives DTC. Conclusions: (1)The hormone receptor status between primary tumor and corresponding DTC is disconcordant. (2)This discrepancy may explain the rate of non-responders to adjuvant endocrine therapy despite ER-positive primary tumors. (3)These patients may benefit from adjuvant therapy regimens based on antibody strategies or bisphosphonates. No significant financial relationships to disclose.

Treg and Teff in the bone marrow of early-stage breast cancer patients with disseminated tumor cells.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e21049-e21049
Author(s):  
D. G. Wolf ◽  
D. Fong ◽  
L. Scherrer ◽  
A. Wolf ◽  
D. Reimer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Tumor Cells ◽  
Early Stage ◽  
Disseminated Tumor Cells ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document